138 related articles for article (PubMed ID: 36763522)
1. Plasticity of lineage switch in B-ALL allows for successful rechallenge with CD19-directed immunotherapy.
Lee BM; Summers C; Chisholm KM; Bohling SD; Leger KJ; Gardner R; Annesley C; Lamble AJ
Blood Adv; 2023 Jun; 7(12):2825-2830. PubMed ID: 36763522
[No Abstract] [Full Text] [Related]
2. A superantigen-antibody fusion protein for T-cell immunotherapy of human B-lineage malignancies.
Gidlöf C; Dohlsten M; Lando P; Kalland T; Sundström C; Tötterman TH
Blood; 1997 Mar; 89(6):2089-97. PubMed ID: 9058731
[TBL] [Abstract][Full Text] [Related]
3. Differentiation of naive cord-blood T cells into CD19-specific cytolytic effectors for posttransplantation adoptive immunotherapy.
Serrano LM; Pfeiffer T; Olivares S; Numbenjapon T; Bennitt J; Kim D; Smith D; McNamara G; Al-Kadhimi Z; Rosenthal J; Forman SJ; Jensen MC; Cooper LJ
Blood; 2006 Apr; 107(7):2643-52. PubMed ID: 16352804
[TBL] [Abstract][Full Text] [Related]
4. Membrane-associated CD19-LYN complex is an endogenous p53-independent and Bc1-2-independent regulator of apoptosis in human B-lineage lymphoma cells.
Myers DE; Jun X; Waddick KG; Forsyth C; Chelstrom LM; Gunther RL; Tumer NE; Bolen J; Uckun FM
Proc Natl Acad Sci U S A; 1995 Oct; 92(21):9575-9. PubMed ID: 7568175
[TBL] [Abstract][Full Text] [Related]
5. B-lineage antigens that are useful to substitute CD19 for minimal residual disease monitoring in B cell precursor acute lymphoblastic leukemia after CD19 targeting.
Mikhailova E; Itov A; Zerkalenkova E; Roumiantseva J; Olshanskaya Y; Karachunskiy A; Novichkova G; Maschan M; Popov A
Cytometry B Clin Cytom; 2022 Sep; 102(5):353-359. PubMed ID: 35796438
[TBL] [Abstract][Full Text] [Related]
6. Chimeric Antigen Receptor-Modified T Cell Immunotherapy for Relapsed and Refractory Adult Burkitt Lymphoma.
Wu J; Cao Y; Zhang Q; Liu W; Zhou X; Ming X; Meng F; Zhang Y; Li C; Huang L; Wei J; Zheng M; Zhang S; Zhang T; Zhu X; Wang N; Wang J; Wang G; Zhou J; Liu B; Xiao Y
Front Immunol; 2022; 13():879983. PubMed ID: 35669773
[TBL] [Abstract][Full Text] [Related]
7. The feasibility of additional CD19-targeted cellular therapy in relapsed/refractory B-ALL with re-emergence of CD19 antigen after prior CD19-negative relapse.
Agrawal V; Salhotra A; Song J; Gu Z; Stein AS; Marcucci G; Forman SJ; Pullarkat V; Aldoss I
Am J Hematol; 2023 Feb; 98(2):E38-E40. PubMed ID: 36413124
[No Abstract] [Full Text] [Related]
8. Sequential anti-CD19, 22, and 20 autologous chimeric antigen receptor T-cell (CAR-T) treatments of a child with relapsed refractory Burkitt lymphoma: a case report and literature review.
Du J; Zhang Y
J Cancer Res Clin Oncol; 2020 Jun; 146(6):1575-1582. PubMed ID: 32222815
[TBL] [Abstract][Full Text] [Related]
9. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia.
Imai C; Mihara K; Andreansky M; Nicholson IC; Pui CH; Geiger TL; Campana D
Leukemia; 2004 Apr; 18(4):676-84. PubMed ID: 14961035
[TBL] [Abstract][Full Text] [Related]
10. Characterization of in vitro migratory properties of anti-CD19 chimeric receptor-redirected CIK cells for their potential use in B-ALL immunotherapy.
Marin V; Dander E; Biagi E; Introna M; Fazio G; Biondi A; D'Amico G
Exp Hematol; 2006 Sep; 34(9):1219-29. PubMed ID: 16939815
[TBL] [Abstract][Full Text] [Related]
11. 15-color highly sensitive flow cytometry assay for post anti-CD19 targeted therapy (anti-CD19-CAR-T and blinatumomab) measurable residual disease assessment in B-lymphoblastic leukemia/lymphoma: Real-world applicability and challenges.
Chatterjee G; Dhende P; Raj S; Shetty V; Ghogale S; Deshpande N; Girase K; Patil J; Kalra A; Narula G; Dalvi K; Dhamne C; Moulik NR; Rajpal S; Patkar NV; Banavali S; Gujral S; Subramanian PG; Tembhare PR
Eur J Haematol; 2024 Jan; 112(1):122-136. PubMed ID: 37706583
[TBL] [Abstract][Full Text] [Related]
12. A comparison of the anti-tumor effects of a chimeric versus murine anti-CD19 immunotoxins on human B cell lymphoma and Pre-B acute lymphoblastic leukemia cell lines.
Tsai LK; Pop LM; Liu X; Vitetta ES
Toxins (Basel); 2011 Apr; 3(4):409-19. PubMed ID: 22069716
[TBL] [Abstract][Full Text] [Related]
13. Durable remissions in two adult patients with Burkitt lymphoma following anti-CD19 CAR T-cell therapy: a single center experience.
Seitter SJ; McClelland PH; Ahlman MA; Goff SL; Yang JC; McIntyre L; Rosenberg SA; Kochenderfer JN; Brudno JN
Leuk Lymphoma; 2022 Oct; 63(10):2469-2473. PubMed ID: 35679521
[No Abstract] [Full Text] [Related]
14. Potentiation by interleukin 2 of Burkitt's lymphoma therapy with anti-pan B (anti-CD19) monoclonal antibodies in a mouse xenotransplantation model.
Vuist WM; v Buitenen F; de Rie MA; Hekman A; Rümke P; Melief CJ
Cancer Res; 1989 Jul; 49(14):3783-8. PubMed ID: 2472198
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of CD22 and CD19 CAR-T bridging auto-HSCT as consolidation therapy for AYA and adult B-ALL.
Qiu Y; Wan CL; Xu MZ; Zhou HX; Liu MJ; Gong WJ; Kang LQ; Sun AN; Yu L; Wu DP; Qian CS; Xue SL
Blood Cancer J; 2023 May; 13(1):66. PubMed ID: 37137904
[No Abstract] [Full Text] [Related]
16. CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy.
Scheuermann RH; Racila E
Leuk Lymphoma; 1995 Aug; 18(5-6):385-97. PubMed ID: 8528044
[TBL] [Abstract][Full Text] [Related]
17. Quantitative flow cytometry can distinguish between normal and leukaemic B-cell precursors.
Farahat N; Lens D; Zomas A; Morilla R; Matutes E; Catovsky D
Br J Haematol; 1995 Nov; 91(3):640-6. PubMed ID: 8555067
[TBL] [Abstract][Full Text] [Related]
18. Effective lysis of lymphoma cells with a stabilised bispecific single-chain Fv antibody against CD19 and FcgammaRIII (CD16).
Bruenke J; Barbin K; Kunert S; Lang P; Pfeiffer M; Stieglmaier K; Niethammer D; Stockmeyer B; Peipp M; Repp R; Valerius T; Fey GH
Br J Haematol; 2005 Jul; 130(2):218-28. PubMed ID: 16029450
[TBL] [Abstract][Full Text] [Related]
19. Radioimmunotherapy for model B cell malignancies using 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies.
Ma D; McDevitt MR; Barendswaard E; Lai L; Curcio MJ; Pellegrini V; Brechbiel MW; Scheinberg DA
Leukemia; 2002 Jan; 16(1):60-6. PubMed ID: 11840264
[TBL] [Abstract][Full Text] [Related]
20. CAR T-cells in relapsed Burkitt lymphoma - a promising test drive in a rare disease.
Erika Haydu J; Abramson JS
Leuk Lymphoma; 2022 Oct; 63(10):2263-2264. PubMed ID: 35856474
[No Abstract] [Full Text] [Related]
[Next] [New Search]
